TELENS-ED: TELENeurological Support for Emergency Department

Sponsor
Azienda Ospedaliero-Universitaria di Modena (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04611295
Collaborator
Azienda USL Modena (Other)
88
2
1
24.9
44
1.8

Study Details

Study Description

Brief Summary

Open-label, non-inferiority, teleconsultation with televisit study to compare efficacy, safety and users satisfaction of a TeleNeurological Support versus "in person" neurological examination in the emergency department

Condition or Disease Intervention/Treatment Phase
  • Procedure: Teleneurological evaluation and support
N/A

Detailed Description

The investigtors are going to perform an interventional, open-label study on the use of teleconsultation in the emergency department focused on neurological diseases other than stroke (for which a specific protocol already exists) in two Hospitals of Modena province, Italy.

The study is aimed at developing a remote neurological consultancy system (teleconsultation) for patients with acute neurological symptoms in charge of hospital facilities without 24-hour availability of neurologist consultant.

Pilot project setting: a) ED of Modena Policlinico Hospital in the afternoon, night, and public holidays, time windows in which the Neurologist consultant is not present at Policlinico Hospital; b) ED of Mirandola Hospital.

The project (enrolment) is expected to be developed over a period of 6 months in which 100 patients will be enrolled.

The primary objective is to assess whether a TeleNeurological Evaluation and Support for the Emergency Department can guarantee a faster but qualitatively not inferior diagnostic/therapeutic work-up if compared with in person examination, assuring the availability of all the necessary examinations and treatments with a consistent time reduction.

Secondary objectives: to determine if the usage of a teleconsultation physician for neurological evaluation compared to a conventional physician "de visu" in urgent but non-life-threatening neurological cases, is superior regarding 1) effect evaluation, 2) process evaluation, and 3) cost-benefit analysis.

Outcome and process indicators will be assessed and compared in the following groups:
  • Experimental group (cases): a) patients who access the Policlinico Hospital ED in the afternoon and night-time and on holidays; b) patients who access the Mirandola Hospital ED during the period of the study.

  • Control Groups: a) retrospectively collected data on neurological consultation performed by OCB Neurology for Policlinico Hospital patients in the same time slots in the same months of the last two years.; b) retrospectively collected data on neurological consultation performed by Carpi Neurology for Mirandola Hospital patients in the same time slots in the same months of the last two years.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
88 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
TELENeurological Evaluation and Support for the Emergency Department (TELENS-ED): an Open-label Clinical Trial
Actual Study Start Date :
Dec 1, 2020
Anticipated Primary Completion Date :
Oct 30, 2022
Anticipated Study Completion Date :
Dec 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Teleneurological evaluation and support

teleneurological evaluation using a medical device certified as telemedicine system

Procedure: Teleneurological evaluation and support
The study is aimed at developing a remote neurological consultancy system (teleconsultation) for patients with acute neurological symptoms in charge of hospital facilities without 24-hour availability of neurologist consultant.

Outcome Measures

Primary Outcome Measures

  1. Teleconsultation clinical application [6 months]

    Percentage of patients who undergo neurological teleconsultation over the number of patients who access on the days and in the time slots in which the service is active and needing a neurological evaluation.

  2. Teleconsultation diagnostic efficacy [6 months]

    Percentage of patients re-admitted to the ED in the 7 days following the date of neurological consultation. It is expected that for the patients of the neurological teleconsultation the % of re-admission to ED will not exceed that of the patients undergone standard neurological advice.

  3. Teleconsultation efficacy - hospitalization [6 months]

    Percentage of hospitalized patients among those undergone TeleNeurology compared to percentage of hospitalization for patients with in person neurological evaluation. It is expected that for patients of the teleneurology group the % of hospitalization will not exceed that of patients undergone standard neurological advice.

  4. Time 'door to end of diagnostic process' [6 months]

    The total time from ED admission to the end of the diagnostic and therapeutic process (time spent in the ED): this time is expected to be significantly shorter for patients in the teleneurology group than for patients having a standard neurological advice.

  5. Time 'door to end of neurological evaluation' [6 months]

    The time from the ED admission to the end of the remote neurological consultation: this time is expected to be significantly shorter for patients in the teleneurology group than for patients having a standard neurological advice

Secondary Outcome Measures

  1. Cost-effectiveness [6 months]

    Evaluation of costs, or cost-effectiveness. For the evaluation of costs, it will be developed a model that considers the cost of the system on the one hand, and the savings in terms of personnel (medical personnel, paramedics and ambulances costs). Outcome indicator.

  2. Evaluation of the level of satisfaction of the users [6 months]

    For this purpose an evaluation form will be provided to patients / family members. Users satisfaction will be measured by visual analogue scale (VAS) where 100 is the highest satisfaction and 0 is the lowest. Outcome indicator.

  3. Evaluation of the level of satisfaction of the health personnel. [6 months]

    For this purpose an evaluation form will be provided to medical personnel involved. Personnel satisfaction will be measured by visual analogue scale (VAS) where 100 is the highest satisfaction and 0 is the lowest. Outcome indicator.

  4. Teleconsultation failure [6 months]

    Percentage of cases assessed by teleconsultation for which the neurologist was unable to make remote decisions and requested for sending the patient to Hub Hospital for a "first-person" evaluation. Process indicator.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged > 18 years

  • Symptoms related to possible acute / subacute neurological pathology, or worsening of known neurological pathology, for which the ED physician considers neurological consultation indicated / necessary.

  • Signing of informed consent to remote neurological evaluation.

Exclusion Criteria:
  • All life-threatening emergency cases, where the study procedure would interfere with clinical practice

  • Patients with known neurological pathology or with clinical severity to such an extent that the need for admission to OCB/Carpi Neurology unit or to the internal wards of the Policlinico is immediately evident.

  • Refusal of the patient/caregiver to perform remote neurological evaluation.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Azienda USL di Modena Modena Italy 41123
2 Azienda Ospedaliero Universitaria di Modena Modena Italy

Sponsors and Collaborators

  • Azienda Ospedaliero-Universitaria di Modena
  • Azienda USL Modena

Investigators

  • Principal Investigator: Antonio Luciani, MD, Azienda Ospedaliero Universitaria Policlinico Modena

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Stefano Meletti, Study coordinator and Clinical Investigator, Azienda Ospedaliero-Universitaria di Modena
ClinicalTrials.gov Identifier:
NCT04611295
Other Study ID Numbers:
  • 942/2020/DISP/AOUMO
First Posted:
Nov 2, 2020
Last Update Posted:
Aug 11, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 11, 2022